Dexpemedolac is long-acting non-narcotic analgesic. Dexpemedolac exhibited potent analgesic effects against chemically induced pain in rats and mice and against inflammatory pain in rats. Dexpemedolac differed from standard nonsteroidal anti-inflammatory drugs (NSAIDs) in that the doses, which produced analgesia were much lower than those required for either anti-inflammatory or gastric irritant effects. The common to the NCAIDs class actions are antipyresis and inhibitory effects on platelet aggregation. In yeast-induced hyperthermic rats, dexpemedolac exhibited antipyretic actions, whereas the drug did not affect body temperature in normothermic animals. Aggregation of human platelets was inhibited by high concentrations of dexpemedolac.

Fenabutene controls pituitary activity.

Fenbenicillin (phenoxybenzylpenicillin) is an acid-stable, orally active penicillin. Fenbenicillin demonstrated antibacterial activity in patients suffering from streptococcal, pneumococcal, and penicillin-sensitive staphylococcal infections.

Fenadiazole is a sedative/hypnotic drug. It has a a unique oxadiazole-based structure. It used to be manufactured by the French pharmaceutical company Laboratoires Jacques Logeais.

Fencibutirol is alpha-cyclohexylbutyric acid derivative. It exerts choleretic activity.

Pentorex (Modatrop) is phenylisopropylamine derivative. It is a central adrenergic stimulant drug related to phentermine, which is used as an anorectic to assist with weight loss. Pentorex is sympathomimetic agent.

Penthrichloral has sedative and hypnotic properties similar to those of chloral hydrate but it is more palatable and causes less gastric irritation. Penthrichloral is a binder for polyester fibers.

Sagopilone (BAY86-5302; ZK 219477; ZK-EPO) is a synthetic epothilone, an analog of patupilone that was developed by Bayer HealthCare as an anticancer agent. Epothilones are 16-member ring macrolides have demonstrated potent antiproliferative activity in several different multidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo. Sagopilone binds to tubulin and induces microtubule polymerization, which may result in the induction of G2/M arrest, and apoptosis. Sagopilone is not a substrate for the P-glycoprotein efflux pump and so may exhibit activity in multidrug-resistant tumors. This drug was studied in clinical trials phase II in patients with recurrent ovarian cancer, in metastatic melanoma patients, for the treatment of advanced stage breast cancer and in the treatment of Glioblastoma patients. However, the development of this drug was discontinued, because of its adverse effects, including peripheral neuropathy.

Picumast is a prophylactically active anti-allergic compound which combines inhibition of mediator release and action. The activity profile of picumast differs clearly from that of known prophylactic anti-allergic drugs such as DSCG and ketotifen. Other inhibitory actions of picumast in addition to its Histamine H1 receptor -antagonism (and that of its metabolites M2 and M1) may be the cause of the suppression of immediate and late phase allergic reactions in animals as well as allergic rhinitis and bronchial responsiveness and symptom scores in asthmatic patients. In the rat, picumast inhibited carrageenin edema but was inactive against other types of inflammation. Picumast dihydrochloride cannot be considered as an anti-inflammatory drug in general, since it was inactive against adjuvant arthritis in rats and did not inhibit cotton pellet granulomas.